GRIMES & Co WEALTH MANAGEMENT LLC Acquires 10,731 Shares of Johnson & Johnson $JNJ

GRIMES & Co WEALTH MANAGEMENT LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 10.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 117,712 shares of the company’s stock after purchasing an additional 10,731 shares during the quarter. GRIMES & Co WEALTH MANAGEMENT LLC’s holdings in Johnson & Johnson were worth $21,826,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Clayton Financial Group LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth about $28,000. Evolution Wealth Management Inc. bought a new stake in Johnson & Johnson during the second quarter worth about $27,000. Semmax Financial Advisors Inc. raised its holdings in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares in the last quarter. GFG Capital LLC acquired a new position in Johnson & Johnson during the second quarter valued at approximately $35,000. Finally, Signature Resources Capital Management LLC increased its position in shares of Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after purchasing an additional 184 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Positive Phase 3 MajesTEC‑9 results: J&J reported topline data showing TECVAYLI (teclistamab) monotherapy cut risk of progression or death by 71% and reduced risk of death by 40% versus standard of care in a hard‑to‑treat multiple myeloma cohort — a result that supports TECVAYLI as a potential earlier standard of care and strengthens future revenue and label expansion prospects. TECVAYLI monotherapy demonstrates superior progression-free and overall survival
• Positive Sentiment: Additional Phase 3 confirmation: Separate coverage highlights Tecvayli’s Phase 3 results showing reduced progression and extended survival in pretreated multiple myeloma patients with manageable safety — reinforcing commercial upside if approvals/label expansions follow. Johnson & Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients
• Positive Sentiment: Legal relief in Auris litigation: J&J won a partial reversal of a roughly $1B loss in the Auris case, reducing a sizable litigation overhang and lowering potential cash/earnings risk tied to the matter. That legal win supports sentiment and removes a tail‑risk. Johnson & Johnson wins partial reversal of $1B Auris case loss
• Neutral Sentiment: Analyst commentary and investor attention: Recent analyst notes review J&J’s fundamentals ahead of the Q4 print and compare J&J to peers; these discussions are keeping the name in focus but do not change near‑term fundamentals by themselves. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Earnings preview and metrics deep‑dive: Coverage previewing J&J’s upcoming Q4 release highlights key non‑GAAP metrics and items to watch (pipeline updates, margin drivers, guidance) — useful for positioning but outcome‑dependent. Exploring Analyst Estimates for Johnson & Johnson (JNJ) Q4 Earnings
• Negative Sentiment: Uncertain beat potential into earnings: Some previews suggest J&J may not have the mix needed for an earnings beat, implying the quarterly report could disappoint relative to expectations and introduce short‑term downside if guidance or key metrics miss. Johnson & Johnson (JNJ) Reports Next Week

Johnson & Johnson Stock Up 0.5%

Shares of JNJ opened at $219.62 on Friday. The firm has a market cap of $529.13 billion, a P/E ratio of 21.20, a price-to-earnings-growth ratio of 2.24 and a beta of 0.34. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $219.75. The firm’s 50-day simple moving average is $205.18 and its 200 day simple moving average is $186.28.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 14th. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.76 by $0.04. The firm had revenue of $23.99 billion during the quarter, compared to the consensus estimate of $23.73 billion. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company’s revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the company posted $2.42 EPS. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Argus set a $210.00 price objective on Johnson & Johnson in a report on Wednesday, October 15th. BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a research note on Monday, October 20th. Stifel Nicolaus raised their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Finally, HSBC reissued a “buy” rating and set a $240.00 price target on shares of Johnson & Johnson in a research report on Wednesday, December 10th. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $213.33.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.